### Overview

Triptodur (triptorelin) is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. Triptodur is FDA indicated for treatment of central precocious puberty (CPP) in patients 2 years and older.

### Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Triptodur excluding when the product is obtained as samples or via manufacturer’s patient assistance programs **OR**

Authorization may be when the following criteria are met, and documentation has been submitted:

1. The member has a diagnosis of CPP with onset of secondary sex characteristics before age eight for females or age nine for males.
2. Member is at least 2 years of age
3. The prescriber is a pediatric endocrinologist or documentation of a consultation with a pediatric endocrinologist is provided
4. The member has had an inadequate response, adverse reaction or a contraindication to Lupron.

### Limitations

1. Approvals will be granted for females up to the age of 12 and up to the age of 13 for males

### References

1. Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; January 2019.

---

![Image](https://example.com/image.png)

4. Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2017


Review History
09/24/18 – Reviewed
01/01/19 – Implemented
09/18/19 – Removed testing requirements, added started & stabilized requirement, and combined male and female criteria

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.